All News

According to various research studies, these are the most commonly used interventions patients consider for treating and managing childhood obesity.

Patients who completed electronic patient-reported outcome measures said they made them feel more involved in their care and better supported.

Learn how one pharmacy chain adopted a cash pricing solution that offered new opportunities for profitability while still offering competitive pricing to customers.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

Albert Dahan, MD, PhD, discusses recent data on Tris Pharma’s first-in-class dual-NMR agonist and how it will fit into the broader landscape of pain management therapies.

In case you missed it, this week we had news about novel treatments for dry eye disease, art therapy and mental health, abdominal fat's role in pain, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Researchers analyzed the outcomes of positive airway pressure therapy for Medicare beneficiaries with obstructive sleep apnea.

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

Researchers conducted a meta-analysis detailing previous patient outcomes in response to visual art therapy interventions.

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

Check out important updates from the FDA for the week of August 9.

Albert Dahan, MD, PhD, professor of anesthesiology at Leiden University Medical Center, talks about the first-in-class dual-NMR agonist cebranopadol.

Findings could inform future clinical practices on the treatment of DED for the more than 400 million people worldwide with the condition.

Industry experts and physicians conducted a state-by-state breakdown of vaccination statistics for children and teenagers as well as adults and elderly individuals.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).

A recent meta-analysis found that supplementing with vitamin D could improve blood pressure, blood lipid levels, and glycemic parameters.

To further understand PBM market concentration, researchers separately analyzed commercial insurance, Medicare Part D, and Medicaid managed care market strategies of the 3 biggest PBMs.

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Researchers looked for a better understanding of medical debt and what type of role the US government plays in lessening the burden on patients and their health care costs.

Viridian Therapeutics also said it has completed enrollment for a second phase 3 trial of veligrotug, THRIVE-2, and expects topline data to be available by the end of this year.

Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.

Data from the SWIFT-1 and SWIFT-2 studies were presented by GSK at the European Respiratory Society International Conference.

The CDC confirmed another human bird flu case, marking the first instance of the virus in a human without occupational exposure to infected birds or dairy cattle during the 2024 outbreak.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

LEO Pharma presented data from 2 of the largest multinational real-world studies on the prevalence, severity and treatment of chronic hand eczema at the European Society of Contact Dermatitis congress.

Check out this recap of articles published on our sister sites during the past week.